Document is current
Any future updates will be listed below
-
Authors
Tungu, Patrick K.
Rowland, Mark W. https://orcid.org/0000-0002-5567-9562
Messenger, Louisa A.
Small, Graham J.
Bradley, John
Snetselaar, Janneke
Kirby, Matthew J.
Mbewe, Njelembo J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05150808 at ClinicalTrials.govDocuments that mention this clinical trial
Large-scale (Phase III) evaluation of broflanilide 50WP (VECTRON™ T500) for indoor residual spraying for malaria vector control in Northeast Tanzania: study protocol for a two-arm, non-inferiority, cluster-randomised community trial
https://doi.org/10.1186/s12879-022-07138-3
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (grant no. OPP1148615)
- License Information
-
More Information
Article History
Received: 26 January 2022
Accepted: 9 February 2022
First Online: 21 February 2022
Declarations
:
: The application of IRS is a National Malaria Control Programme (NMCP) policy. IRS will be used in line with recommendations from the manufacturers and WHO. The WHO has accepted that the IRS products do not present a hazard according to WHO risk assessment models. Consent to participate was obtained in writing from leaders of all villages selected to participate and from all heads of families randomly selected for entomological surveillance or focus group discussions (FGDs). Adverse effects, reported by households sprayed with IRS will be noted during the community perception surveys. Any discomfort tends to arise during the first two weeks after IRS is sprayed in houses. Consenting families will be forewarned on the informed consent form. Medical attention will be given to affected people free of cost. Confidentiality of the FGDs and survey respondents will be addressed by giving them unique anonymised identifiers. Participants’ identity will not be revealed in any reports or publications resulting from the study. Medical confidentiality will be preserved. All data will be collected on record sheets stamped with unique IDs so that they can be traced. Any information collected will not be disclosed by the study staff to anyone except where required by law and regulations. Ethical clearance has been obtained from the Tanzanian National Institute of Medical Research Ethics Committee and Ethics Committee of LSHTM. Trial registration is recorded with clinicaltrials.gov. Sponsorship of the trial is provided by the LSHTM Research Governance and Integrity Office.
: Not applicable.
: The authors declare that they have no competing interests.
